© 2021 MJH Life Sciences and Oncology Nursing News. All rights reserved.
© 2021 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
October 25, 2021
Health care professionals who treated patients throughout the COVID-19 pandemic and received CBD therapy reported less burnout and emotional exhaustion than those solely receiving standard-of-care treatment.
This holistic approach will allow you to discover your unique blueprint for well-being in life rather than focusing solely on amassing wealth.
October 24, 2021
Approximately 73% of patients with NMIBC who experienced a complete response after non-surgical primary chemoablation using mitomycin-containing reverse thermal gel UGN-102 remained disease free at 9 months.
October 23, 2021
The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.
October 22, 2021
A recent study identified some of the key challenges in coordinated care for underinsured and uninsured cancer survivors who have initiated the surveillance stage of their journey.
October 21, 2021
Rather than encouraging patients to acknowledge their sickness, it’s more valuable to have them recognize their wellness.
Inguinofemoral radiotherapy may be a safe alternative for patients with vulvar cancer and sentinel node micrometastases who might otherwise face the morbidity of a lymphadenectomy.
October 20, 2021
Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, comments on how health care providers can effectively care for patients with COVID-19 and hematologic malignancies.
A speaker at the Oncology Nursing Society Bridge Program discussed how nurses can build their own resilience and proactively protect their mental well-being.
October 19, 2021
Sintilimab, a bevacizumab biosimilar injection, met the primary end point of the phase 3 ORIENT-31 trial by significantly increasing progression-free survival in patients with EGFR-mutated, nonsquamous, non–small cell lung cancer.